{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:38:47Z","timestamp":1759970327745,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["72374167"],"award-info":[{"award-number":["72374167"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Introduction: Spinal muscular atrophy is a rare genetic disease. Nusinersen and Risdiplam, recognized as disease-modifying therapies, were included in the National Reimbursement Drug List in 2022 and 2023, respectively, in China. Policies have been implemented to enhance a multi-level medical security system, particularly for rare diseases. This study explores the self-perceived burden and offers policy suggestions to improve China\u2019s social security for rare diseases. Methods: In our mixed study, we conducted 37 semi-structured online interviews and a quantitative survey with 3 adult SMA patients and 34 family members (primary caregivers) in collaboration with the Meier Advocacy and Support Center. The interviews explored self-perceived burdens in psychology, domestic relations, medical care, rehabilitation, and economy, analyzing mainly through thematic analysis and multiple linear regression. Results: Respondents reported significant psychological burdens mainly stemming from limited treatment access. The instability within these families was linked to inconsistent therapeutic schedules, the lack of development opportunities, and misunderstandings. Choices between institutional and home rehabilitation were influenced by economic conditions and symptom severity. After the inclusion of medications, six patients (16.2%) still had not received pharmacological treatment, and many of those who underwent treatment were dissatisfied with the outcomes. The high costs of rehabilitation, family labor loss, and an incomplete medical security system resulted in significant economic burdens. Respondents called for more effective medications and better patient support. Conclusion: Although the inclusion of medications in National Reimbursement Drug List has improved availability and affordability, families still experienced significant burdens across multiple domains. A broader focus on social security is needed to enhance the comprehensive development of patients with rare diseases.<\/jats:p>","DOI":"10.3390\/healthcare13020140","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T05:40:40Z","timestamp":1736746840000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiences of Family Members and Patients with Spinal Muscular Atrophy Under the Multi-Level Medical Security System in Shaanxi Province, China: A Mixed Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7128-960X","authenticated-orcid":false,"given":"Yuhan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0238-4699","authenticated-orcid":false,"given":"Chenglong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University, 76 Yanta West Road, Xi\u2019an 710061, China"},{"name":"Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University, Xi\u2019an 710061, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13023-021-01701-y","article-title":"\u201cI have SMA, SMA doesn\u2019t have me\u201d: A qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA","volume":"16","author":"Mazzella","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s41687-024-00758-0","article-title":"Identification of the most relevant aspects of spinal muscular atrophy (SMA) with impact on the quality of life of SMA patients and their caregivers: The PROfuture project, a qualitative study","volume":"8","author":"Lemus","year":"2024","journal-title":"J. Patient-Rep. Outcomes"},{"key":"ref_4","unstructured":"Medical Genetics Branch of Beijing Medical Associatio, and Beijing Rare Disease Diagnosis and Protection Associatio (2020). Consensus on genetic diagnosis of spinal muscular atrophy. Natl. Med. J. China, 100, 3130\u20133140."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41436-020-0890-6","article-title":"Patient and family social media use surrounding a novel treatment for a rare genetic disease: A qualitative interview study","volume":"22","author":"Iyer","year":"2020","journal-title":"Genet. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: Diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.vhri.2022.08.015","article-title":"Budget Impact Analysis of Nusinersen for Spinal Muscular Atrophy in China","volume":"34","author":"Duan","year":"2023","journal-title":"Value Health Reg. Issues"},{"key":"ref_9","first-page":"109","article-title":"Defining Disease Modifying Therapy for Alzheimer\u2019s Disease","volume":"4","author":"Cummings","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2024, October 25). FDA Approves First Drug for Spinal Muscular Atrophy, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (2024, October 25). FDA Approves Oral Treatment for Spinal Muscular Atrophy, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mus.28015","article-title":"A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy","volume":"69","author":"Powell","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_14","unstructured":"U.S. Food and Drug Administration (2024, December 14). FDA Approves Innovative Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy, a Rare Disease and Leading Genetic Cause of Infant Mortality, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40265-024-02051-2","article-title":"Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians","volume":"84","author":"Ramdas","year":"2024","journal-title":"Drugs"},{"key":"ref_16","unstructured":"National Healthcare Security Administration, and Ministry of Human Resources and Social Security of the People\u2019s Republic of China (2024, October 25). Notice on the Issuance of the National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Directory (2022), Available online: https:\/\/www.nhsa.gov.cn\/art\/2023\/1\/18\/art_104_10078.html."},{"key":"ref_17","unstructured":"National Healthcare Security Administration, and Ministry of Human Resources and Social Security of the People\u2019s Republic of China (2024, October 25). Notice on the Issuance of the National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Directory (2021), Available online: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2021-12\/03\/content_5655651.htm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e240118","DOI":"10.57264\/cer-2024-0118","article-title":"Managing the challenges of paying for gene therapy: Strategies for market action and policy reform in the United States","volume":"13","author":"Phares","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737175.2024.2439486","article-title":"Treatment strategies for patients with spinal muscular atrophy","volume":"10","author":"Waele","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"ref_20","unstructured":"The State Council of the People\u2019s Republic of China (2024, October 25). Opinions on Deepening the Reform of the Medical Security System, Available online: https:\/\/www.gov.cn\/zhengce\/2020-03\/05\/content_5487407.htm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11192-014-1406-4","article-title":"A bibliometric study of China\u2019s science and technology policies: 1949\u20132010","volume":"102","author":"Huang","year":"2015","journal-title":"Scientometrics"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Li, X., Wu, L., Yu, L., He, Y., Wang, M., and Mu, Y. (2023). Policy analysis in the field of rare diseases in China: A combined study of content analysis and Bibliometrics analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1180550"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13023-019-1052-2","article-title":"\u201cGetting ready for the adult world\u201d: How adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being","volume":"14","author":"Wan","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-023-02739-w","article-title":"Barriers and facilitating factors of care coordination for children with spinal muscular atrophy type I and II from the caregivers\u2019 perspective: An interview study","volume":"18","author":"Willems","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40271-020-00415-w","article-title":"\u201cThe Whole Game is Changing and You\u2019ve Got Hope\u201d: Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy","volume":"13","author":"Farrar","year":"2020","journal-title":"Patient"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., Ho, C.S., and Ho, R.C. (2020). Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17051729"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1475-6773.2006.00684.x","article-title":"Qualitative data analysis for health services research: Developing taxonomy, themes, and theory","volume":"42","author":"Bradley","year":"2007","journal-title":"Health Serv. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jpc.12993","article-title":"\u201cA short time but a lovely little short time\u201d: Bereaved parents\u2019 experiences of having a child with spinal muscular atrophy type 1","volume":"52","author":"Higgs","year":"2016","journal-title":"J. Paediatr. Child Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13023-022-02407-5","article-title":"Parents as informal caregivers of children and adolescents with spinal muscular atrophy: A systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs","volume":"17","author":"Brandt","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/jan.13042","article-title":"Living with illness and self-transcendence: The lived experience of patients with spinal muscular atrophy","volume":"72","author":"Ho","year":"2016","journal-title":"J. Adv. Nurs."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Boursange, S., Araneda, M., Stalens, C., Desguerre, I., Barnerias, C., Nougues, M.C., Isapof, S., Quijano-Roy, S., Genestine, N.B., and Ouillade, L. (2022). Parents\u2019 dilemma: A therapeutic decision for children with spinal muscular atrophy (SMA) type 1. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.1062390"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pedn.2018.09.007","article-title":"Identifying Opportunities to Provide Family-centered Care for Families with Children With Type 1 Spinal Muscular Atrophy","volume":"43","author":"Murrell","year":"2018","journal-title":"J. Pediatr. Nurs."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: Expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13561-024-00519-1","article-title":"Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: A scoping review","volume":"14","author":"Ng","year":"2024","journal-title":"Health Econ. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/jpc.15507","article-title":"Rare diseases research and policy in Australia: On the journey to equitable care","volume":"57","author":"Bhattacharya","year":"2021","journal-title":"J. Paediatr. Child Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bomhof, C.H.C., Smids, J., Sybesma, S., Schermer, M., and Bunnik, E.M. (2023). Ethics of access to newly approved expensive medical treatments: Multi-stakeholder dialogues in a publicly funded healthcare system. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1265029"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Scheijmans, F.E., Zomers, M.L., Fadaei, S., Onrust, M.R., van der Graaf, R., Delden, J.J.V., van der Pol, W.L., and van Thiel, G.J. (2022). The reimbursement for expensive medicines: Stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08690-z"},{"key":"ref_39","first-page":"816","article-title":"Parents\u2019 perspectives on nusinersen treatment for children with spinal muscular atrophy","volume":"3","author":"Ketelaar","year":"2021","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-180330","article-title":"Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy","volume":"6","author":"Pacione","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s13023-021-01943-w","article-title":"Navigating the U.S. health insurance landscape for children with rare diseases: A qualitative study of parents\u2019 experiences","volume":"16","author":"Pasquini","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/archdischild-2023-325762","article-title":"Understanding caregiver experiences with disease-modifying therapies for spinal muscular atrophy: A qualitative study","volume":"108","author":"Xiao","year":"2023","journal-title":"Arch. Dis. Child"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13023-020-01477-7","article-title":"Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: A longitudinal qualitative study","volume":"15","author":"Kiefer","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5152\/TurkArchPediatr.2021.20117","article-title":"The Burden of Primary Caregivers of Spinal Muscular Atrophy Patients and Their Needs","volume":"56","author":"Ergenekon","year":"2021","journal-title":"Turk. Arch. Pediatr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e57353","DOI":"10.2196\/57353","article-title":"Patterns of the Health and Economic Burden of 33 Rare Diseases in China: Nationwide Web-Based Study","volume":"10","author":"Yu","year":"2024","journal-title":"JMIR Public Health Surveill."}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/2\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:27:47Z","timestamp":1759919267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/2\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["healthcare13020140"],"URL":"https:\/\/doi.org\/10.3390\/healthcare13020140","relation":{},"ISSN":["2227-9032"],"issn-type":[{"type":"electronic","value":"2227-9032"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}